New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).